CUBT Stock Chart & Stats
$1.00
$0.03(3.40%)
At close: 4:00 PM EDT
$1.00
$0.03(3.40%)
Day’s Range― - ―
52-Week Range$0.03 - $5.00
Previous CloseN/A
Volume1.25K
Average Volume (3M)181.23K
Market Cap
$6.68M
Enterprise Value$10.21M
Total Cash (Recent Filing)$145.26K
Total Debt (Recent Filing)$1.36M
Price to Earnings (P/E)―
Beta-0.62
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding6,819,907
10 Day Avg. Volume67,116
30 Day Avg. Volume181,230
Financial Highlights & Ratios
PEG Ratio2.71
Price to Book (P/B)-135.42
Price to Sales (P/S)0.00
P/FCF Ratio-948.65
Enterprise Value/Market Cap1.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-117.19
Enterprise Value/Ebitda-8.92
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CUBT FAQ
What was Curative Biotechnology’s price range in the past 12 months?
Curative Biotechnology lowest stock price was $0.03 and its highest was $5.00 in the past 12 months.
What is Curative Biotechnology’s market cap?
Curative Biotechnology’s market cap is $6.68M.
When is Curative Biotechnology’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Curative Biotechnology’s earnings last quarter?
Curative Biotechnology released its earnings results on May 25, 2021. The company reported -$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.002.
Is Curative Biotechnology overvalued?
According to Wall Street analysts Curative Biotechnology’s price is currently Overvalued.
Does Curative Biotechnology pay dividends?
Curative Biotechnology does not currently pay dividends.
What is Curative Biotechnology’s EPS estimate?
Curative Biotechnology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Curative Biotechnology have?
Curative Biotechnology has 6,819,907 shares outstanding.
What happened to Curative Biotechnology’s price movement after its last earnings report?
Curative Biotechnology reported an EPS of -$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Curative Biotechnology?
Currently, no hedge funds are holding shares in CUBT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Curative Biotechnology
Curative Biotechnology, Inc. is an emerging biomedical firm primarily focused on developing pharmaceutical products. Its research and development efforts are concentrated on a diverse pipeline targeting critical therapeutic areas, including infectious diseases, cancer, and vision-impairing degenerative eye conditions. Among its key pipeline assets is IMT504, an innovative immunotherapy designed for rabies treatment and as a vaccine enhancer. Another prominent candidate is CUBT906, a fully humanized CD56 monoclonal antibody that delivers a pyrrolobenzodiazepine dimer directly to tumor cells, aiming to eradicate them by halting their growth and spread. Additionally, the company is advancing a reformulated Metformin for the management of degenerative eye disorders. Curative Biotechnology has entered into a licensing and co-development partnership with Mid-Atlantic BioTherapeutics, Inc. to further advance IMT504, specifically for addressing advanced rabies and as a component of a COVID-19 vaccine. Previously known as Connectyx Technologies Holdings Group, Inc., the company adopted its current name, Curative Biotechnology, Inc., in November 2020. Established in 1995, the company maintains its headquarters in Boca Raton, Florida.